Enanta Pharmaceuticals (ENTA) EBT Margin (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly EBT Margin came in at 76.25% in Q1 2026, up 8420.0% YoY from 0.89% in Q1 2025, and down 19.14% on a QoQ basis from 64.0% in Q4 2025.
Powered by 
Analysis
Enanta Pharmaceuticals (ENTA) EBT Margin (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of EBT Margin data on file, last reported at 76.25% in Q1 2026.
- Quarterly EBT Margin rose 8420.0% year-over-year to 76.25% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 89.42% (up 6399.0% YoY) and the FY2025 annual result came in at 127.9%, up 4625.0% from the prior year.
- EBT Margin declined to 76.25% in Q1 2026, from 64.0% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 64.0% in Q4 2025 to a low of 211.37% in Q1 2023.
- A 5-year average of 147.55% and a median of 155.91% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2023 — EBT Margin plunged 6597 bps — and 2026, when it jumped 8420 bps.
- Tracing ENTA's EBT Margin over 5 years: stood at 123.04% in 2022, then plunged by 54 bps to 189.02% in 2023, then advanced by 29 bps to 133.89% in 2024, then surged by 52 bps to 64.0% in 2025, then decreased by 19 bps to 76.25% in 2026.
- The last three EBT Margin figures came in at 76.25% (Q1 2026), 64.0% (Q4 2025), and 123.42% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Enanta Pharmaceuticals | 409.30 Mn | 219.79 Mn | - | -135.56% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -135.56% |
| Mar 31, 2026 | -76.25% |
| Dec 31, 2025 | -64.00% |
| Sep 30, 2025 | -123.42% |
| Jun 30, 2025 | -99.52% |
| Mar 31, 2025 | -160.45% |
| Dec 31, 2024 | -133.89% |
| Sep 30, 2024 | -199.81% |
| Jun 30, 2024 | -128.28% |
| Mar 31, 2024 | -184.82% |
| Dec 31, 2023 | -189.02% |
| Sep 30, 2023 | -155.91% |
| Jun 30, 2023 | -184.44% |
| Mar 31, 2023 | -211.37% |
| Dec 31, 2022 | -123.04% |
| Sep 30, 2022 | -129.62% |
| Jun 30, 2022 | -165.03% |
| Mar 31, 2022 | -179.48% |
| Dec 31, 2021 | -109.05% |
| Sep 30, 2021 | -141.65% |